News for Daré Bioscience, Inc. (DARE)

A first-of-its-kind solution for women's arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work

A first-of-its-kind solution for women's arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Monday. The Dow traded up 0.05% to 44,393.18 while the NASDA...

Daré Bioscience, Inc. (DARE) stock surged 250% to over $9 after positive interim Phase 3 trial results for Ovaprene, a hormone-free, monthly intravaginal contraceptive, with the Data Safety Monitoring Board recommending continuation without modification. The trial showed a 9% pregnancy rate among treated women, consistent with prior studies, positioning Ovaprene…

U.S. stocks traded slightly lower this morning, with the Dow Jones index falling around 0.1% on Monday. Following the market opening Monday, the Dow traded dow...

Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive SAN DIEGO, July 14, 2025

Daré Bioscience (DARE) receives a $6 million non-dilutive grant installment, totaling $37.8 million of a potential $49 million commitment. The grant su

**media[653584]**

Collaboration will leverage Rosy Wellness' extensive reach and community of over 250,000 women Rosy Wellness is a multi-award winning app recommended by 8,000+

Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ETCompany ParticipantsMarDee Haring-Layton - Chief Accounting...

In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. ( DARE), a biopharmaceutical company driven by a mission to challenge the status quo, makin

Presentation will focus on corporate communications strategies for unveiling an innovative expanded business strategyDaré recently announced its new dual-path

Daré Bioscience's Q4 2024 earnings highlight a dual-path strategy for Sildenafil Cream, targeting 2025 revenue with 503B compounding while advancing FDA...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. ( DARE), a leader in innovation for the health and well-being of women, will host a conf

**media[568943]**

**media[534060]**

**media[510775]**

The panel will discuss the value proposition for investing in women's health. J.P. Morgan is hosting a three-panel women's health series at this year's confere